The recent media coverage on benzoyl peroxide (BPO), a popular acne treatment ingredient, has brought to light concerns about the presence of benzene, a known carcinogen, in various BPO-containing products. Independent testing laboratory Valisure conducted a comprehensive study and found that when BPO products were subjected to elevated temperatures, they could decompose and form benzene at levels significantly exceeding the FDA's conditional limit of 2 parts per million (ppm) for benzene in drug products. This discovery has raised significant safety concerns among dermatologists, consumers, and regulatory bodies.

 

Valisure's investigation involved testing 66 BPO products, including creams, lotions, gels, and washes, both over-the-counter and prescription. The study revealed that some products contained benzene levels up to 12 times the FDA's allowed amount, with the concentration of benzene increasing further when products were exposed to higher temperatures designed to simulate potential product degradation over time. Among the products tested, some notable brands were found to have high levels of benzene, prompting Valisure to file a Citizen's Petition with the FDA, urging a recall of the affected treatments.

 

The findings are particularly alarming because benzene is not just a contaminant but is formed due to the instability of BPO itself, especially under conditions like those found in hot environments such as bathrooms or cars. This decomposition process not only increases benzene levels in the product over time but can also lead to benzene being released into the air from the product's packaging, posing an inhalation risk.

 

These revelations have sparked a broader conversation about product safety and stability testing, especially for products containing BPO. It highlights the importance of stringent regulatory oversight and the need for manufacturers to ensure that their products remain safe throughout their entire lifecycle, from production to expiration.

 

Valisure's findings and the subsequent media coverage underscore the critical role independent testing laboratories play in safeguarding public health. They also emphasize the need for consumers and healthcare providers to be aware of the potential risks associated with commonly used skincare products and to take appropriate precautions, such as proper storage of BPO-containing products to minimize benzene formation.

 

The dermatology community, including esteemed figures like Dr. Christopher Bunick, Associate Professor of Dermatology at Yale University, has been quick to respond to these findings. There is a consensus that while BPO is an effective treatment for acne, the potential risks associated with benzene formation cannot be overlooked, and there is a need for further investigation to address these safety concerns.

In the meantime, it is important for consumers to look for alternatives to their benzoyl peroxide products. The CLn skin clarifying acne wash is formulated without BPO, but with 0.5% salicylic acid. The formula is a proprietary combination of salicylic acid, sodium hypochlorite, and surfactants, that treats acne breakouts and blemishes, while not discoloring clothing and towels.

Disclaimer: Unless otherwise explicitly stated, the content on this blog, including all articles, videos, and other information, is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The views expressed on this blog and website have no relation to those of any academic, hospital, health practice, or other institution.